Immunology Biosimilars Market Report 2026

The immunology biosimilars market size has grown rapidly in recent years. It will grow from $8.35 billion in 2025 to $9.45 billion in 2026 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to high cost of original biologics, limited availability of biosimilar alternatives, growing prevalence of autoimmune diseases, increasing hospital and clinical adoption of biologics, stringent regulatory approvals for biosimilars.

The immunology biosimilars market size is expected to see rapid growth in the next few years. It will grow to $15.3 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to development of advanced biosimilar molecules, expansion of homecare and outpatient treatment options, increasing regulatory harmonization, rising patient awareness and acceptance, growth of online and hospital pharmacy distribution channels. Major trends in the forecast period include rising adoption of monoclonal antibody biosimilars, increasing use of fusion protein biosimilars, expansion of recombinant protein therapies, growing market for interferon-based treatments, enhanced access to affordable immunology therapies.

The growing prevalence of chronic immunological conditions is expected to drive the expansion of the immunology biosimilars market in the coming years. Chronic immunological conditions are long-term disorders in which the immune system either attacks the body’s own tissues or fails to protect it adequately. The rise in these conditions is driven by an increasing number of individuals affected by persistent immune system disorders that require ongoing treatment, proactive disease management, and continuous healthcare support. Immunology biosimilars play a key role in managing chronic immunological conditions by providing cost-effective and efficient treatment alternatives, facilitating long-term disease control, and improving patient access to therapies that regulate immune system dysfunction. For example, in November 2023, the Multiple Sclerosis International Federation (MSIF), a UK-based nonprofit organization focused on global MS research and advocacy, reported that approximately 2.9 million people worldwide were living with multiple sclerosis in 2023. This indicates that the rising prevalence of chronic immunological conditions is driving growth in the immunology biosimilars market.

Leading companies in the immunology biosimilars market are concentrating on developing next-generation biosimilar innovations, including anticipated interchangeability designations, advanced formulations with improved stability, and novel delivery systems, to offer patients more effective and accessible treatment options. An anticipated interchangeability designation signifies that a biosimilar is expected to meet regulatory standards, allowing it to be substituted for the reference biologic at the pharmacy level without prescriber intervention. For instance, in February 2025, Sandoz Group AG, a Switzerland-based pharmaceutical company, launched Pyzchiva (ustekinumab-ttwe), a biosimilar to Stelara, for treating chronic autoimmune conditions such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This launch, in collaboration with Samsung Bioepis Co. Ltd., a South Korea-based biopharmaceutical company, underscores Sandoz’s commitment to expanding access to immunology biosimilars by providing cost-effective, patient-centric therapies with multiple dosing options, enhanced stability, and the unique feature of being re-refrigerated after initial refrigeration.

In February 2025, Accord BioPharma Inc., a U.S.-based healthcare company, partnered with Bio‑Thera Solutions Co., Ltd. for BAT2506, a proposed golimumab biosimilar. Through this collaboration, Accord BioPharma aimed to broaden its immunology biosimilar portfolio in the U.S. by acquiring commercialization rights for a late-stage TNF‑α-blocking biosimilar. Bio‑Thera Solutions Co., Ltd., a China-based biopharmaceutical company, specializes in developing, manufacturing, and supplying innovative biosimilars, including immunology assets such as BAT2506.

Major companies operating in the immunology biosimilars market are Pfizer Inc., Novartis AG, Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Samsung Bioepis Co. Ltd., Gedeon Richter Plc, Celltrion Inc., Biocon Ltd., Innovent Biologics Inc., Biocad, Mabion S.A.

North America was the largest region in the immunology biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the immunology biosimilars market by increasing costs for imported biologic production equipment, raw materials, and reagents. Segments like monoclonal antibodies and recombinant proteins are particularly affected, with Asia-Pacific regions including India and China facing higher import duties. This has led to supply chain challenges and higher treatment costs in certain markets. Positively, tariffs have promoted local manufacturing, encouraged domestic R&D investments, and accelerated production of cost-effective biosimilars.

The immunology biosimilars market research report is one of a series of new reports that provides immunology biosimilars market statistics, including immunology biosimilars industry global market size, regional shares, competitors with a immunology biosimilars market share, detailed immunology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the immunology biosimilars industry. This immunology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immunology biosimilars are biologic medical products that closely resemble already approved original biologic drugs used to treat immune-related disorders, with no meaningful differences in safety, purity, or effectiveness. They offer more cost-effective treatment options for patients with conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, thereby improving access to essential therapies.

The main categories of immunology biosimilars include monoclonal antibodies, fusion proteins, recombinant proteins, interferons, and others. Monoclonal antibodies are lab-engineered molecules designed to replicate the immune system’s ability to combat harmful pathogens like viruses or bacteria. These therapies are applied to multiple diseases, including inflammatory bowel disease, arthritis, and others. They are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are utilized by a range of end users including hospitals, clinics, homecare settings, and ambulatory surgical centers (ASCs).

The immunology biosimilars market consists of sales of tumor necrosis factor inhibitors, recombinant cytokines, t-cell co-stimulation modulators, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.